A study to investigate the effect of iclaprim in patients with hospital acquired bacterial pneumonia
Phase of Trial: Phase III
Latest Information Update: 02 Mar 2016
At a glance
- Drugs Iclaprim (Primary)
- Indications Nosocomial pneumonia
- Focus Registrational; Therapeutic Use
- Sponsors Motif Bio
- 28 Jul 2015 New trial record
- 15 Apr 2015 According to a Motif Bio media release, the FDA has agreed to the proposed phase III clinical development programme for iclaprim. The FDA confirmed that two ABSSSI trials or one ABSSSI trial plus one HABP trial meeting their pre-specified primary endpoints are required for approval of iclaprim.
- 15 Apr 2015 According to a Motif Bio media release, this trial is expected to being in the second half of 2015.